Andere Sprachen Nuvectis Pharma, Inc.

Aktien

A3C8W7

US67080T1088

NVCT

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 14.06.2024			% 5 Tage	% 1. Jan.
6,77 ^USD	-0,88 %		+6,78 %	-18,82 %

07.05.	Nuvectis Pharma, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024	CI
08.04.	Nxp900 von Nuvectis Pharma zeigt robuste Aktivität bei nicht-kleinzelligen Lungenkrebs-Zelllinien	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference	16.05.
Nuvectis Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights	07.05.
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08.04.
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08.04.
Nuvectis Pharma's Nxp900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines	08.04.
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting	19.03.
Nuvectis Pharma to Present at the 36th Annual Roth Conference	15.03.
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer	14.03.
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer	14.03.
Nuvectis Pharma, Inc. Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant Arid1a-Mutated Ovarian Cancer	14.03.
Nuvectis Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	05.03.
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights	05.03.
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences	09.02.
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences	09.02.
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03.01.
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03.01.
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma	18.12.
Nuvectis Pharma, Inc. Reports Third Quarter 2023 Financial Results and Business Highlights	08.11.
Nuvectis Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	08.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Nuvectis Pharma, Inc.

Aktien

A3C8W7

US67080T1088

NVCT

Andere Sprachen

Filter